These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 15993811)

  • 21. GPCR targeted library design: novel dopamine D3 receptor ligands.
    Böcker A; Sasse BC; Nietert M; Stark H; Schneider G
    ChemMedChem; 2007 Jul; 2(7):1000-5. PubMed ID: 17477344
    [No Abstract]   [Full Text] [Related]  

  • 22. Dopamine D3 receptor antagonists in pathologic gambling.
    Bou Khalil R
    J Clin Psychopharmacol; 2013 Feb; 33(1):146-8. PubMed ID: 23288245
    [No Abstract]   [Full Text] [Related]  

  • 23. F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum.
    Bruins Slot LA; Lestienne F; Grevoz-Barret C; Newman-Tancredi A; Cussac D
    Eur J Pharmacol; 2009 Oct; 620(1-3):27-35. PubMed ID: 19695244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug seeking under a second-order schedule of reinforcement depends on dopamine D3 receptors in the basolateral amygdala.
    Di Ciano P
    Behav Neurosci; 2008 Feb; 122(1):129-39. PubMed ID: 18298256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Action of novel antipsychotics at human dopamine D3 receptors coupled to G protein and ERK1/2 activation.
    Bruins Slot LA; Palmier C; Tardif S; Cussac D
    Neuropharmacology; 2007 Aug; 53(2):232-41. PubMed ID: 17588617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia.
    Gross G; Wicke K; Drescher KU
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Feb; 386(2):155-66. PubMed ID: 23128852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological modulation of functional connectivity: the correlation structure underlying the phMRI response to d-amphetamine modified by selective dopamine D3 receptor antagonist SB277011A.
    Schwarz AJ; Gozzi A; Reese T; Heidbreder CA; Bifone A
    Magn Reson Imaging; 2007 Jul; 25(6):811-20. PubMed ID: 17442525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Dopamine D3 receptors as a novel target for improving the treatment of schizophrenia].
    Millan MJ
    Med Sci (Paris); 2005 Apr; 21(4):434-42. PubMed ID: 15811310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective antagonism at dopamine D3 receptors as a target for drug addiction pharmacotherapy: a review of preclinical evidence.
    Heidbreder C
    CNS Neurol Disord Drug Targets; 2008 Nov; 7(5):410-21. PubMed ID: 19128200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
    Millan MJ; Mannoury la Cour C; Novi F; Maggio R; Audinot V; Newman-Tancredi A; Cussac D; Pasteau V; Boutin JA; Dubuffet T; Lavielle G
    J Pharmacol Exp Ther; 2008 Feb; 324(2):587-99. PubMed ID: 18024789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced apomorphine sensitivity and increased binding of dopamine D2 receptors in nucleus accumbens in prepubertal rats after neonatal blockade of the dopamine D3 receptors by (+)-S14297.
    Flores-Tochihuitl J; Vargas G; Morales-Medina JC; Rivera G; De La Cruz F; Zamudio S; Flores G
    Synapse; 2008 Jan; 62(1):40-9. PubMed ID: 17957737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The selective dopamine D3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats.
    Gyertyán I; Sághy K
    Eur J Pharmacol; 2007 Oct; 572(2-3):171-4. PubMed ID: 17628535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopamine D3 as well as D2 receptor ligands attenuate the cue-induced cocaine-seeking in a relapse model in rats.
    Gál K; Gyertyán I
    Drug Alcohol Depend; 2006 Jan; 81(1):63-70. PubMed ID: 16005579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The structural evolution of dopamine D3 receptor ligands: structure-activity relationships and selected neuropharmacological aspects.
    Boeckler F; Gmeiner P
    Pharmacol Ther; 2006 Oct; 112(1):281-333. PubMed ID: 16905195
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Studies towards the identification of a new generation of atypical antipsychotic agents.
    Garzya V; Forbes IT; Gribble AD; Hadley MS; Lightfoot AP; Payne AH; Smith AB; Douglas SE; Cooper DG; Stansfield IG; Meeson M; Dodds EE; Jones DN; Wood M; Reavill C; Scorer CA; Worby A; Riley G; Eddershaw P; Ioannou C; Donati D; Hagan JJ; Ratti EA
    Bioorg Med Chem Lett; 2007 Jan; 17(2):400-5. PubMed ID: 17084080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rationale in support of the use of selective dopamine D₃ receptor antagonists for the pharmacotherapeutic management of substance use disorders.
    Heidbreder C
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Feb; 386(2):167-76. PubMed ID: 23104235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and SAR of highly potent and selective dopamine D(3)-receptor antagonists: Quinolin(di)one and benzazepin(di)one derivatives. herve.geneste@abbott.com.
    Geneste H; Backfisch G; Braje W; Delzer J; Haupt A; Hutchins CW; King LL; Lubisch W; Steiner G; Teschendorf HJ; Unger L; Wernet W
    Bioorg Med Chem Lett; 2006 Feb; 16(3):658-62. PubMed ID: 16271293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
    Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of D(3) dopamine receptors blockade on the cognitive effects of angiotensin IV in rats.
    Braszko JJ; Wielgat P; Walesiuk A
    Neuropeptides; 2008 Jun; 42(3):301-9. PubMed ID: 18359517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amphetamine decreases behavioral inhibition by stimulation of dopamine D2, but not D3, receptors.
    van Gaalen MM; Unger L; Jongen-Rêlo AL; Schoemaker H; Gross G
    Behav Pharmacol; 2009 Sep; 20(5-6):484-91. PubMed ID: 19696659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.